Pfizer and the French-Swiss firm Valneva say trials have shown a 70% efficacy rate in people aged five and above.

Submission based on favorable efficacy and safety results from Phase 3 VALOR trial NEW YORK & LYON, France, August, 14, 2026 Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) ...

Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for ...

Previously, a vaccine called LYMErix was administered to prevent Lyme disease. It was approved by the FDA in 1998, but ...

EU officials have agreed to study an experimental vaccine against Lyme disease, the world's most common tick-borne illness, ...

Prime Minister Jacinda Ardern announced the strategy Monday, saying the decision was based on the Pfizer vaccine's ...

After reporting mixed clinical results in a phase 3 trial, Pfizer and Valneva have filed their Lyme disease vaccine candidate PF-07307405 in the EU, and the EMA has started its review. The six-valent ...

The central protrusion, essentially a barbed straw, secretes germ-ridden saliva and sucks up the blood of the ...

Respiratory syncytial virus, or RSV, is dangerous for certain adults and babies. Here is the latest information on ...

EMA validates marketing authorisation application of Pfizer & Valneva’s PF-07307405, a 6-valent OspA-based Lyme disease vaccine: New York Monday, August 17, 2026, 11:00 Hrs [IST ...

The Boise and West Ada school districts began classes Aug. 12, which is the most recent day for which the wastewater data is ...

The rate of miscarriage among pregnant women who received the COVID-19 vaccine is not 82% — that figure comes from a misinterpretation of a 2021 study. Studies have consistently shown the rate of ...